Efficacy and safety of high-dose Xueshuantong injection (lyophilised) in reducing the incidence of major adverse cardiovascular events in patients with unstable angina: a protocol of a randomised, parallel-arm, controlled, double-blind and multicentre clinical trial based on dual antiplatelet therapy.
Wenjie LongHuili LiaoXi HuangQingqing LiuYaqing TangLiming LuJianhong LiuTianhui YuanYan LingYu HongJiao DuanWeiji LinShaoxiang XianZhongqi YangPublished in: BMJ open (2020)
This study was registered on the Chinese Clinical Trial Registry (http://www.chictr.org.cn/) with the ID ChiCTR1800015911.
Keyphrases
- clinical trial
- double blind
- cardiovascular events
- antiplatelet therapy
- coronary artery disease
- percutaneous coronary intervention
- high dose
- placebo controlled
- study protocol
- phase ii
- acute coronary syndrome
- open label
- phase iii
- cardiovascular disease
- randomized controlled trial
- low dose
- coronary artery
- stem cell transplantation
- lymph node metastasis
- atrial fibrillation
- ultrasound guided
- cross sectional